About Tonix Pharmaceuticals Holding Corp.
https://www.tonixpharma.comTonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates.
CEO
Seth Lederman
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-02-05 | Reverse | 1:100 |
| 2024-06-10 | Reverse | 1:32 |
ETFs Holding This Stock
Summary
Showing Top 3 of 52
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:681.53K
Value:$11.52M
VANGUARD GROUP INC
Shares:556.96K
Value:$9.41M
GEODE CAPITAL MANAGEMENT, LLC
Shares:200.93K
Value:$3.4M
Summary
Showing Top 3 of 61
About Tonix Pharmaceuticals Holding Corp.
https://www.tonixpharma.comTonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $3.29M ▲ | $34.99M ▲ | $-32.01M ▼ | -972.95% ▲ | $-3.59 ▲ | $-31.55M ▼ |
| Q2-2025 | $2M ▼ | $27.02M ▲ | $-28.27M ▼ | -1.42K% ▼ | $-3.86 ▼ | $-27.81M ▼ |
| Q1-2025 | $2.43M ▼ | $17.54M ▼ | $-16.83M ▲ | -692.84% ▲ | $-2.84 ▲ | $-16.34M ▲ |
| Q4-2024 | $2.58M ▼ | $23.88M ▲ | $-22.11M ▼ | -856.24% ▼ | $-9.77 ▼ | $-21.61M ▼ |
| Q3-2024 | $2.82M | $16.82M | $-14.21M | -503.65% | $-0.23 | $-15.04M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $190.06M ▲ | $252.44M ▲ | $21.3M ▲ | $231.14M ▲ |
| Q2-2025 | $125.33M ▼ | $187.36M ▼ | $19.36M ▲ | $168M ▼ |
| Q1-2025 | $131.72M ▲ | $192.87M ▲ | $12.47M ▼ | $180.4M ▲ |
| Q4-2024 | $98.78M ▲ | $162.89M ▲ | $23.33M ▲ | $139.56M ▲ |
| Q3-2024 | $28.23M | $94.99M | $20.78M | $74.21M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-32.01M ▼ | $-28.78M ▼ | $-962K ▲ | $94.86M ▲ | $65.11M ▲ | $-29.74M ▼ |
| Q2-2025 | $-28.27M ▼ | $-14.83M ▲ | $-2.54M ▼ | $10.99M ▼ | $-6.38M ▼ | $-17.37M ▼ |
| Q1-2025 | $-16.83M ▲ | $-16.58M ▼ | $-6K ▼ | $49.53M ▼ | $32.94M ▼ | $-16.59M ▼ |
| Q4-2024 | $-22.11M ▼ | $-14.63M ▲ | $-3K ▲ | $85.15M ▲ | $70.54M ▲ | $-14.63M ▲ |
| Q3-2024 | $-14.21M | $-18.8M | $-9K | $42.91M | $24.08M | $-18.81M |
CEO
Seth Lederman
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-02-05 | Reverse | 1:100 |
| 2024-06-10 | Reverse | 1:32 |
ETFs Holding This Stock
Summary
Showing Top 3 of 52
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:681.53K
Value:$11.52M
VANGUARD GROUP INC
Shares:556.96K
Value:$9.41M
GEODE CAPITAL MANAGEMENT, LLC
Shares:200.93K
Value:$3.4M
Summary
Showing Top 3 of 61